An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Human immunoglobulin (Ig) is the most commonly used blood product. It has been well-defined
the efficacy in patients with immunodeficiencies, Kawasaki disease, asthma and other immune
diseases. It is expected that Ig 10% will improve the usefulness and safety profile compared
to Ig 5% because it is expected the reduced hospitalization/treatment duration and less
adverse events related to volume overload.